Quality of life in survivors of oropharyngeal cancer: A systematic review and meta-analysis of 1366 patients

Sanne Høxbroe Michaelsen; Christian Grønhøj; Jacob Høxbroe Michaelsen; Jeppe Friborg; Christian von Buchwald

doi:10.1016/j.ejca.2017.03.006

Quality of life in survivors of oropharyngeal cancer: A systematic review and meta-analysis of 1366 patients

Sanne Høxbroe Michaelsen, Christian Grønhøj, Jacob Høxbroe Michaelsen, Jeppe Friborg, Christian von Buchwald

Department of Clinical Medicine

57 Citations (Scopus)

Abstract

Human papillomavirus (HPV)-associated oropharyngeal cancer (OPC) is rapidly increasing in incidence and has a favourable prognosis compared with HPV-negative disease. Current combined therapies include significant risks of morbidity for the growing group of survivors. This systematic review and meta-analysis investigates how treatment affects quality of life (QoL) in survivors of oropharyngeal cancer. PubMed, EMBASE and the Cochrane Library were systematically searched for all studies reporting patient-assessed QoL at least 1 year after treatment for OPC. In a meta-analysis, weighted average QoL scores from the four most commonly utilised QoL instruments were compared with baseline and reference group scores using the concept of minimal clinically important difference. The meta-analysis included data from 1366 patients from 25 studies and 12 countries. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) was answered by 704 patients, 644 patients answered the EORTC QLQ Head and Neck-35 (H&N-35), 474 patients answered the University of Washington Quality of Life Questionnaire, and 381 patients answered the M. D. Anderson Dysphagia Inventory. Moderate to large clinically important deteriorations in QoL were found in the domains dry mouth and sticky saliva for the EORTC QLQ-H&N35, saliva, chewing, swallowing, speech, taste, appearance and shoulder for the University of Washington Quality of Life Questionnaire, and the global, physical and emotional subscales for the M. D. Anderson Dysphagia Inventory. In conclusion, survivors of OPC face clinically important deteriorations in QoL that most markedly centre on xerostomia, dysphagia and chewing. These ailments indicate a potential for improvement in patient management.

Original language	English
Journal	European Journal of Cancer
Volume	78
Pages (from-to)	91-102
ISSN	0959-8049
DOIs	https://doi.org/10.1016/j.ejca.2017.03.006
Publication status	Published - 1 Jun 2017

Keywords

Adult
Aged
Combined Modality Therapy
Deglutition Disorders/etiology
Female
Humans
Male
Mastication/physiology
Middle Aged
Oropharyngeal Neoplasms/complications
Papillomavirus Infections/complications
Psychiatric Status Rating Scales
Quality of Life/psychology
Surveys and Questionnaires
Survivors/psychology
Xerostomia/etiology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ejca.2017.03.006

Cite this

@article{b69efbe230ad4fdc8168c34d8bb37bb9,

title = "Quality of life in survivors of oropharyngeal cancer: A systematic review and meta-analysis of 1366 patients",

abstract = "Human papillomavirus (HPV)-associated oropharyngeal cancer (OPC) is rapidly increasing in incidence and has a favourable prognosis compared with HPV-negative disease. Current combined therapies include significant risks of morbidity for the growing group of survivors. This systematic review and meta-analysis investigates how treatment affects quality of life (QoL) in survivors of oropharyngeal cancer. PubMed, EMBASE and the Cochrane Library were systematically searched for all studies reporting patient-assessed QoL at least 1 year after treatment for OPC. In a meta-analysis, weighted average QoL scores from the four most commonly utilised QoL instruments were compared with baseline and reference group scores using the concept of minimal clinically important difference. The meta-analysis included data from 1366 patients from 25 studies and 12 countries. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) was answered by 704 patients, 644 patients answered the EORTC QLQ Head and Neck-35 (H&N-35), 474 patients answered the University of Washington Quality of Life Questionnaire, and 381 patients answered the M. D. Anderson Dysphagia Inventory. Moderate to large clinically important deteriorations in QoL were found in the domains dry mouth and sticky saliva for the EORTC QLQ-H&N35, saliva, chewing, swallowing, speech, taste, appearance and shoulder for the University of Washington Quality of Life Questionnaire, and the global, physical and emotional subscales for the M. D. Anderson Dysphagia Inventory. In conclusion, survivors of OPC face clinically important deteriorations in QoL that most markedly centre on xerostomia, dysphagia and chewing. These ailments indicate a potential for improvement in patient management.",

keywords = "Adult, Aged, Combined Modality Therapy, Deglutition Disorders/etiology, Female, Humans, Male, Mastication/physiology, Middle Aged, Oropharyngeal Neoplasms/complications, Papillomavirus Infections/complications, Psychiatric Status Rating Scales, Quality of Life/psychology, Surveys and Questionnaires, Survivors/psychology, Xerostomia/etiology",

author = "{H{\o}xbroe Michaelsen}, Sanne and Christian Gr{\o}nh{\o}j and {H{\o}xbroe Michaelsen}, Jacob and Jeppe Friborg and {von Buchwald}, Christian",

year = "2017",

month = jun,

day = "1",

doi = "10.1016/j.ejca.2017.03.006",

language = "English",

volume = "78",

pages = "91--102",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Pergamon",

}

TY - JOUR

T1 - Quality of life in survivors of oropharyngeal cancer

T2 - A systematic review and meta-analysis of 1366 patients

AU - Høxbroe Michaelsen, Sanne

AU - Grønhøj, Christian

AU - Høxbroe Michaelsen, Jacob

AU - Friborg, Jeppe

AU - von Buchwald, Christian

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Human papillomavirus (HPV)-associated oropharyngeal cancer (OPC) is rapidly increasing in incidence and has a favourable prognosis compared with HPV-negative disease. Current combined therapies include significant risks of morbidity for the growing group of survivors. This systematic review and meta-analysis investigates how treatment affects quality of life (QoL) in survivors of oropharyngeal cancer. PubMed, EMBASE and the Cochrane Library were systematically searched for all studies reporting patient-assessed QoL at least 1 year after treatment for OPC. In a meta-analysis, weighted average QoL scores from the four most commonly utilised QoL instruments were compared with baseline and reference group scores using the concept of minimal clinically important difference. The meta-analysis included data from 1366 patients from 25 studies and 12 countries. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) was answered by 704 patients, 644 patients answered the EORTC QLQ Head and Neck-35 (H&N-35), 474 patients answered the University of Washington Quality of Life Questionnaire, and 381 patients answered the M. D. Anderson Dysphagia Inventory. Moderate to large clinically important deteriorations in QoL were found in the domains dry mouth and sticky saliva for the EORTC QLQ-H&N35, saliva, chewing, swallowing, speech, taste, appearance and shoulder for the University of Washington Quality of Life Questionnaire, and the global, physical and emotional subscales for the M. D. Anderson Dysphagia Inventory. In conclusion, survivors of OPC face clinically important deteriorations in QoL that most markedly centre on xerostomia, dysphagia and chewing. These ailments indicate a potential for improvement in patient management.

AB - Human papillomavirus (HPV)-associated oropharyngeal cancer (OPC) is rapidly increasing in incidence and has a favourable prognosis compared with HPV-negative disease. Current combined therapies include significant risks of morbidity for the growing group of survivors. This systematic review and meta-analysis investigates how treatment affects quality of life (QoL) in survivors of oropharyngeal cancer. PubMed, EMBASE and the Cochrane Library were systematically searched for all studies reporting patient-assessed QoL at least 1 year after treatment for OPC. In a meta-analysis, weighted average QoL scores from the four most commonly utilised QoL instruments were compared with baseline and reference group scores using the concept of minimal clinically important difference. The meta-analysis included data from 1366 patients from 25 studies and 12 countries. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) was answered by 704 patients, 644 patients answered the EORTC QLQ Head and Neck-35 (H&N-35), 474 patients answered the University of Washington Quality of Life Questionnaire, and 381 patients answered the M. D. Anderson Dysphagia Inventory. Moderate to large clinically important deteriorations in QoL were found in the domains dry mouth and sticky saliva for the EORTC QLQ-H&N35, saliva, chewing, swallowing, speech, taste, appearance and shoulder for the University of Washington Quality of Life Questionnaire, and the global, physical and emotional subscales for the M. D. Anderson Dysphagia Inventory. In conclusion, survivors of OPC face clinically important deteriorations in QoL that most markedly centre on xerostomia, dysphagia and chewing. These ailments indicate a potential for improvement in patient management.

KW - Adult

KW - Aged

KW - Combined Modality Therapy

KW - Deglutition Disorders/etiology

KW - Female

KW - Humans

KW - Male

KW - Mastication/physiology

KW - Middle Aged

KW - Oropharyngeal Neoplasms/complications

KW - Papillomavirus Infections/complications

KW - Psychiatric Status Rating Scales

KW - Quality of Life/psychology

KW - Surveys and Questionnaires

KW - Survivors/psychology

KW - Xerostomia/etiology

U2 - 10.1016/j.ejca.2017.03.006

DO - 10.1016/j.ejca.2017.03.006

M3 - Review

C2 - 28431302

SN - 0959-8049

VL - 78

SP - 91

EP - 102

JO - European Journal of Cancer

JF - European Journal of Cancer